Molbrick Overview
Molbrick is a start-up developing novel antimicrobial agents to treat drug-resistant mycobacteria. It has designed small-molecule target cellular compartments that are essential for DNA replication. Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
Latest News
No news articles.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
1
Employees: 1-10
Web & Social Links
Locations
Beer-Sheva, Israel
Photos & Videos
No files yet
Molbrick Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMicroorganismsTags (2)
pharmaceuticalsmicrobiologyMolbrick Financials
Molbrick Lifecycle
Molbrick News
0 articlesNo news articles.
Molbrick Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Molbrick Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 86/100 |
| Missing | homepage, news, video or image, funding rounds, markets, external profile |
| BI Verification | Jenny Sotnik-Talisman |
| Creator | Hilla Gorokhovsky |
| Creator email | hilla.gorokhovsky@sncentral.org |
| Last updater | Jenny Sotnik-Talisman |
| Updater email | genys30@yahoo.com |
| Last update | 2021-07-11T00:00:00.000Z |
| Created | 2019-09-08T00:00:00.000Z |
| Claimed | Yes |